Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety trial of its lead cell therapy treatment, NSI-566, in eight patients who have become complete paralyzed due to spinal-cord injuries. Neuralstem has already conducted 18 successful surgeries using the same cells and surgical device that it will use in the new trial. (PR)
Neuralstem (CUR) jumps 12.1% after it receives approval from the FDA to start a Phase I safety...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs